Summary: Step by step, Teva’s management is making progress in transforming it from a generic
Summary: Teva Pharmaceutical’s stock is up 69% since December, driven by legal resolution, blockbuster drugs,
Summary: Since Richard Francis became CEO in early 2023, his ‘Pivot to Growth’ strategy has
Summary: Teva Pharmaceutical stock has been trending higher since October 2023, closing at nearly $16.00.
Summary: Teva’s Q1 earnings show continued momentum, with a 5% increase in total revenue and
Summary: Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations, and
Summary: Teva’s stock has risen 32% since December, outperforming the SPY, buoyed by FDA approval
Summary: Teva Pharmaceutical’s financial performance is not strong, with high debt, lack of margin improvements,
Summary: Teva Pharmaceutical has experienced a significant downturn in the last decade but has recently
Summary: I am upgrading Teva Pharmaceutical to “Buy” for 2024, buoyed by opioid litigation resolution